Talazoparib (BMN 673)

Catalog No.S7048 Synonyms: LT-673

For research use only.

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Talazoparib (BMN 673) Chemical Structure

CAS No. 1207456-01-6

Selleck's Talazoparib (BMN 673) has been cited by 168 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Other PARP Products

Biological Activity

Description Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features Most potent and selective PARPi reported thus far.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1] In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BR5FVB1-Akt MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Lfm94OC5zLUGwNEBvVQ>? MYCyOE81QC95MjDo M4rFe4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NYTIU4VlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFc3QTdpPkK2NFQ4Pjl5PD;hQi=>
BR5FVB1-Akt M3zvVWFxd3C2b4Ppd{BCe3OjeR?= NIC2cJoxNjFvMUCwJI5O MlLhO|IhcA>? NGHGdGhqdmS3Y3XzJIFxd3C2b4Ppdy=> NWCyeXBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFc3QTdpPkK2NFQ4Pjl5PD;hQi=>
Capan-1 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4LkFihKnDueLCiUWuOQKBkcL3TdMg NVLCSFVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlQ2QTBpPkK1PFY1PTlyPD;hQi=>
MIA PaCa-2 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom1TWM2OD13OD6yN-KBkcLz4pEJPE4y6oDLwsXNxsA> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEW5NEc,OjV6NkS1PVA9N2F-
RD M2D1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn3To9KSzVyPUiuO{BvVQ>? NWPYUmxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
Rh41 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxTWM2OD16LkGgcm0> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Rh18 NUL2N3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHbZRKSzVyPUSuPUBvVQ>? MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
Rh30 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLndlJKSzVyPUOxMlEhdk1? NIDHTIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
BT-12 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRuLCiUGsNFAxKG6P NFn5ZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
CHLA-266 NHXF[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWN4lKSzVyPvMAjVEtODByIH7N MmLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
TC-71 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHOfXlKSzVyPUOuO{BvVQ>? MkLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-9 NEnZSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TTPGlEPTB;OD6yJI5O NV6xT5l3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
CHLA-10 M2\teGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[xTWM2OD14Nz64JI5O Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-258 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fmUGlEPTB;ND62JI5O MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
SJ-GBM2 NH35NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF4LkKgcm0> NEj2PW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
NB-1643 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrveWg5UUN3ME2xPE41KG6P NWPx[ohxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
NB-EBc1 NIX6O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{niXWlEPTB;MkWuPEBvVQ>? M2\LSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-90 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRuLCiUGsNFAxKG6P M{\EeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-136 M3viVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF2LkKgcm0> MojiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
NALM-6 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwb2lEPTB;NEmgcm0> M1e5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
COG-LL-317 M3LYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnlc3M3UUN3ME25MlQhdk1? M1myW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
RS4;11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXYS|VKSzVyPUWyMlYhdk1? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
MOLT-4 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntSlhkUUN3ME2xOk43KG6P MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
CCRF-CEM M1;UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmzc4Q5UUN3ME22PVcvOyCwTR?= NVe3O4FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
Kasumi-1 NUnmb3ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm2TWM2OD15OE[uNkBvVQ>? NWnxOWpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
Karpas-299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjJe3kyUUN3ME23OU44KG6P NUPhWVQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
Ramos-RA1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToTI01UUN3ME22PE4{KG6P NUf3SXlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
DT40 NV2ybZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe2V3FzUUN3ME20JI5O M3zOWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W2PFE{Lz5{NEO1OlgyOzxxYU6=
DU145 NFzvc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD1zMTDuUS=> Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
H209 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LSXGlEPTB;MT63JI5O MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H1048 M37mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkW2lEPTB;Mj6yJI5O NYnacndpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H524 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX73TJd3UUN3ME2zMlEhdk1? M13QelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H1930 M4iyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHziUJhKSzVyPUSuNUBvVQ>? M3K1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H69 M3PJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwMjDuUS=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB5N{O1NEc,OjRyN{ezOVA9N2F-
H2081 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLEcHBKSzVyPU[uN{BvVQ>? NEDFUZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H2107 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTdwMzDuUS=> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB5N{O1NEc,OjRyN{ezOVA9N2F-
H1092 NYm0U4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLqTWM2OD16Lkmgcm0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB5N{O1NEc,OjRyN{ezOVA9N2F-
DMS-79 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\4PVlKSzVyPUmuN{BvVQ>? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB5N{O1NEc,OjRyN{ezOVA9N2F-
H446 NVPsWVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF|IH7N NHTl[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
COR-L279 M4q4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3IH7N NX7QOGRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
LoVo M2DlN2Z2dmO2aX;uJIF{e2G7 MWKzNEBucW6| MXvFR|UxKD1iMD6wNFI2KM7:TR?= MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
MX1 NXXRdotFS3m2b4TvfIlkcXS7IHHzd4F6 MVjFR|UxKD1iMD6wNFA{KM7:TR?= NULaUHlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
LoVo NIq2NmRHfW6ldHnvckBie3OjeR?= MmDlN|AhdWmwcx?= NHfqcWJGSzVyIE2gNE4xODJ3MTFOwG0> NXHIPGcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
LoVo NWXobnZoS3m2b4TvfIlkcXS7IHHzd4F6 M1HyfVAvPCC3TR?= MVe1JIRigXN? NEL0[llIUTVyIE2gNE4xODRizszN MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
Capan1 NXfRcWtDS3m2b4TvfIlkcXS7IHHzd4F6 Mlv0SWM2OCB;IECuNFA2KM7:TR?= NGLCOlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MRC5 NVKwTmVzS3m2b4TvfIlkcXS7IHHzd4F6 MkPESWM2OCB;IECuN|Eh|ryP MkLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MX1 NYnyeoJETnWwY4Tpc44h[XO|YYm= MYmxJI1oN2up MoDSNkAtQCCjbnSgNlQhcHK| Ml7zSIVkemWjc3WgbY4hWEGUIHzleoVtKGmwIHH0bJlucWNiboWvcpUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCPWEGgZ4VtdHNiYYSgNUBu\y:tZzygdI8h[WSvaX7pd5RmemWmIHHzJJNqdmeuZTDkc5NmKG2nYYP1doVlKGGodHXyJFIhNDhiYX7kJFI1KGi{czDifUBGVEmVQR?= M1X5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 NHviVmxCdnSrdIXtc5Ih[XO|YYm= NF62WJgxNjN|IH3nM4to M1;mSVI5KGSjeYO= NVTIeVR3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhSlKFQUGg[IVncWOrZX70JIh2dWGwIF3YNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCjdHj5cYlkKG63L371JI1wfXOnIHH0JFAvOzNibXevb4ctKHCxIIHkJIFldWmwaYP0[ZJm\CCob4KgNlgh\GG7cx?= M2fZUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 MoHBRY51cXS3bX;yJIF{e2G7 MmH4NE4yPjVibXevb4c> MWeyPEBl[Xm| M4npbWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGJTS0FzIHTl[olkcWWwdDDoeY1idiCPWEGgZ4VtdHNieHXuc4dz[W[2ZXSgbY4h[XSqeX3pZ{BvfS:wdTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCwMlE3PSCvZz;r[{wheG9iYXTtbY5qe3SncnXkJJR4cWOnIHGg[IF6KG[xcjCyPEBl[Xm| MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MX1 NH7qZlFHfW6ldHnvckBie3OjeR?= MUiwMlM{KG2pL3vn MXrQc5RmdnSrYYTpc44hd2ZiY3HyZo9xdGG2aX6tbY5lfWOnZDD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCxZjDCVmNCOSCmZX\pZ4lmdnRiaIXtZY4hVVhzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpUwdnVibX;1d4Uh[XRiMD6zN{Bu\y:tZzDwc{BidmRiYX7pcYFteyC5ZYLlJJRz\WG2ZXSge4l1cCClYYLic5Bt[XSrbjDheEA{PSCvZz;r[{whcXBib36g[IF6KDF? NE\tbHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MDA-MB-436 NEfPXGxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmPBO{Bl[Xm| M{LFSmlEPTBiPTCwMlAxODdizszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ7MkmxOkc,Ojh4OUK5NVY9N2F-
Capan1 MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVnrZnI2PyCmYYnz NH;aNHdKSzVyIE2gNE4xODF6IN88US=> M2HqW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkmyPVE3Lz5{OE[5NlkyPjxxYU6=
VC8 Mn;6R5l1d3SxeHnjbZR6KGG|c3H5 MVezJIRigXN? MWLJR|UxKD1iMD6wNFQzKM7:TR?= NFKzPYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[5NlkyPid-Mki2PVI6OTZ:L3G+
V79 M3z5eGN6fG:2b4jpZ4l1gSCjc4PhfS=> MkLwN{Bl[Xm| MXHJR|UxKD1iNT6wNVE1KM7:TR?= NHLlblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[5NlkyPid-Mki2PVI6OTZ:L3G+
Capan1 NEHD[WNHfW6ldHnvckBie3OjeR?= NXK1O444OC5zIIXN MVG0JIhzew>? NWW5c3dqUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDCVmNCOiCmZX\pZ4lmdnRiaIXtZY4hS2GyYX6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFCDUmCxMWRPSSC2cnHwdIlv\yCjdDCwMlEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NUXnfI5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PVI6OTZpPkK4OlkzQTF4PD;hQi=>
MDA-MB-436 M3TkZ2Z2dmO2aX;uJIF{e2G7 NGm4XmMyKHWP MkfzOEBpenN? MVXJcohq[mm2aX;uJI9nKFCDUmCxJIlvKEKUQ1GxJIRm\mmlaXXueEBpfW2jbjDNSGEuVUJvNEO2JINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFCDUmCxMWRPSSC2cnHwdIlv\yCjdDCxJJVOKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NWP5[JJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PVI6OTZpPkK4OlkzQTF4PD;hQi=>
Assay
Methods Test Index PMID
Western blot cleaved-PARP / cleaved-caspase3 / γ-H2AX ; pKAP1 / pChk2 / pChk1 ; PD-L1 ; p-ATM 29158830 28947502 28167507 30472087
Growth inhibition assay Cell viability 29158830
Immunofluorescence cleaved PARP / 53BP1 ; RAD51 28958991 30621214
In vivo In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]

Protocol (from reference)

Animal Research:

[2]

  • Animal Models: MX-1 model (BRCA-1 deficient)
  • Dosages: 0.33 mg/kg/day, once daily
  • Administration: Oral

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 380.35
Formula

 

C19H14F2N6O
 
CAS No. 1207456-01-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05425862 Not yet recruiting Drug: Pidnarulex|Drug: Talazoparib Metastatic Castration Resistant Prostate Cancer (mCRPC) Peter MacCallum Cancer Centre Australia July 12 2022 Phase 1
NCT05141708 Active not recruiting Drug: Talazoparib Metastatic Breast Cancer|Breast Neoplasms Pfizer December 17 2021 --
NCT05053854 Recruiting Drug: Talazoparib Neuroendocrine Tumors Peter MacCallum Cancer Centre Australia September 27 2021 Phase 1
NCT04991480 Recruiting Drug: ART4215|Drug: Talazoparib|Drug: Niraparib Advanced Cancer|Metastatic Cancer|Breast Cancer Artios Pharma Ltd September 13 2021 Phase 1|Phase 2
NCT04987931 Completed Drug: Talazoparib Breast Cancer Pfizer August 20 2021 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Which solvent do you recommend to dilute the inhibitor for in vivo study in mice?

Answer:
BMN673 (S7048) can be dissolved in vehicle (10% DMAc, 6% Solutol, and 84% PBS) according to the paper: http://clincancerres.aacrjournals.org/content/19/18/5003.full. Quote from Method and Material section "Xenograft experiments: BMN 673 (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage"

Tags: buy Talazoparib (BMN 673) | Talazoparib (BMN 673) supplier | purchase Talazoparib (BMN 673) | Talazoparib (BMN 673) cost | Talazoparib (BMN 673) manufacturer | order Talazoparib (BMN 673) | Talazoparib (BMN 673) distributor